ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

IMMX vs LXRX // REVENUE GROWTH (YOY)

Immix Biopharma Inc. (NASDAQ) VS. Lexicon Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: IMMX 3 — LXRX 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (IMMX VS. LXRX) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC IMMX LXRX SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 96.00% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -31.50% -3.50 LXRX /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -3.73% -10.30% +6.57 IMMX /fcf-yield <GO>
Operating Margin — -60.00% — TIE /operating-margins <GO>
Net Profit Margin — -60.00% — TIE /net-margins <GO>
Revenue Growth (YoY) ACTIVE — 180.00% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 5/9 -3.00 LXRX /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 30.3 29.1 +1.22 IMMX /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $661.6M $658.5M $3.0M IMMX /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR IMMX REV LXRX REV IMMX GROSS % LXRX GROSS % IMMX FCF LXRX FCF
FY 2025 $0 $49.8M — 98.0% -$24.7M -$67.9M
FY 2024 $0 $6.0M — 89.7% -$15.8M -$179.8M
FY 2023 $0 $1.1M — — -$11.4M -$161.9M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
IMMX // BETA —
LXRX // BETA —